Latest News

Review some of the top stories from the Contemporary OB/GYN website over the past week and catch up on anything you may have missed.

Explore innovative menopause management strategies for BRCA carriers, including testosterone therapy, to alleviate symptoms and enhance quality of life.

Research at The Menopause Society 2025 meeting highlighted safety, education, and individualized care in menopause management.

A new study finds that 1-mg/day dienogest offers comparable pain reduction to a 2-mg/day dose for endometriosis while maintaining a favorable safety profile.

Declining national screening rates highlight the need for increased investment, education, and innovative approaches to expand access.

The updated guideline offers evidence-based recommendations for diagnosing and managing menopause.

Study finds women on hormone therapy lost more weight with tirzepatide, though researchers stress association—not causation—needs confirmation.

Fertility expert Lucky Sekhon, MD, and Olympic gold medalist Tara Lipinski discuss the psychological challenges of infertility.

New data suggest hormone therapy may increase autoimmune disease risk in postmenopausal women, highlighting the need for clinical vigilance.

A large analysis found that stillbirths occur more often than CDC estimates, and many cases lack identifiable clinical risk factors.

Experts highlight future research in personalized menopause care, exploring hormone safety, the microbiome, cognition, and metabolic health.

Experts compare hormone and nonhormonal options for menopause, emphasizing tailored care, persistent symptom relief, and safe use of local estrogen.

Experts discuss how neurokinin receptor antagonists offer rapid, durable, and nonhormonal relief for vasomotor symptoms, reshaping menopause care.

Experts discuss neurokinin receptor drugs, CBT, and lifestyle tools for managing vasomotor symptoms, emphasizing innovation and evidence-based care.

Experts discuss contraindications to hormone therapy and evolving care for women with early or surgical menopause, emphasizing individualized treatment.

Experts review updated VMS treatment guidelines and stress shared decision-making to personalize hormone and nonhormone therapy options.

Experts emphasize normalizing menopause discussions early to reduce stigma and improve communication in both clinical and workplace settings.

Experts discuss how culture, stigma, and inequities shape menopause care and leave many women without adequate symptom management.

Experts highlight education, equity, and access gaps in vasomotor symptom care, calling for stronger clinician training and awareness.

Experts discuss updates in the management of vasomotor symtpoms in menopause, including unmet needs, quality of life impacts, and new therapies.

Nearly 30% of long COVID patients show signs of postural orthostatic tachycardia syndrome, a condition tied to worsened fatigue and recovery.

Erin Donnelly Michos, MD, discusses optimizing cardiovascular disease prevention in women through earlier risk assessment and tailored management.

Earlier menopause accelerates memory decline in women with APOE ε4 or inflammation, highlighting sex-specific Alzheimer disease risk factors.

Estrogen decline during menopause alters fat, muscle, and lipid metabolism; multimodal lifestyle strategies help reduce cardiovascular risk.

Early intervention during perimenopause can prevent long-term osteoporosis through timely screening and intermittent therapy strategies.

A systematic review found estrogen-based hormone therapy did not consistently reduce anxiety or depression in midlife women.

A new study finds that earlier menopause and reduced cardiac function may together worsen brain health, highlighting dementia risk factors.

Cynthia Stuenkel, MD, reviews diagnosis, management, and fertility considerations in women with primary ovarian insufficiency.

CBT adapted for menopause shows benefits for vasomotor symptoms, mood, and sleep, according to Danette Conklin, PhD, at The Menopause Society.

Elinzanetant shows a strong safety profile with no liver toxicity and minimal side effects in menopausal women with vasomotor symptoms.

Following positive safety and efficacy data, the FDA has approved elinzanetant to manage vasomotor symptoms in postmenopausal women.